Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 10/2011

Open Access 01-10-2011 | Editorial

Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past

Authors: Hans-Iko Huppertz, Dirk Föll, Hermann Girschick, Kirsten Minden, Gerd Horneff

Published in: Rheumatology International | Issue 10/2011

Login to get access

Excerpt

What you have inherited from your fathers, acquire it in order to possess it
[Was du ererbt von deinen Vätern hast, erwirb es, um es zu besitzen]
Goethe
Faust
…
Literature
1.
Petty RE, Southwood TR, Baum J et al (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 25:1991–1994PubMed
2.
Aletaha D, Neogi T, Silman AJ et al (2010) Rheumatoid arthritis classification criteria. Arthritis Rheum 62:2569–2581PubMedCrossRef
3.
Beukelman T, Patkar NM, Saag KG et al (2011) American college of rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 63:465–482CrossRef
4.
Dannecker G (2007) Polyarthritis. In: Wagner N, Dannecker G (eds) Pädiatrische Rheumatologie. Springer, Heidelberg
5.
Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthriti. N Engl J Med 359:810–820PubMedCrossRef
6.
Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763–769PubMedCrossRef
7.
Brewer EJ, Giannini EH, Kuzmina N, Alekseev L (1986) Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.–U.S.S.R. double-blind placebo-controlled trial. N Engl J Med 314:1269–1276
8.
Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini FA et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50:2191–2201
9.
Ruperto N, Lovell DJ, Quartier P et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial. Lancet 372:383–391PubMedCrossRef
10.
Horneff G, De Bock F, Foeldvari I et al (2009) German and Austrian Paediatric Rheumatology Collaborative Study Group. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68:519–525PubMedCrossRef
11.
Prince FH, Twilt M, ten Cate R et al (2009) Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 68:635–641PubMedCrossRef
12.
Southwood TR, Foster HE, Davidson JE et al (2011) Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 50:189–195CrossRef
13.
Giannini EH, Ilowite NT, Lovell DJ et al (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60:2794–2804PubMedCrossRef
14.
Foell D, Wulffraat N, Wedderburn LR et al (2010) Methotrexate withdrawal at 6 versus 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303:1266–1273PubMedCrossRef
Metadata
Title
Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past
Authors
Hans-Iko Huppertz
Dirk Föll
Hermann Girschick
Kirsten Minden
Gerd Horneff
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 10/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2062-0

Other articles of this Issue 10/2011

Rheumatology International 10/2011 Go to the issue

Original Article

Increased CD28 serum levels are not associated with specific clinical activity in systemic lupus erythematosus

Original Article

Cholecystokinin octapeptide exerts its therapeutic effects on collagen-induced arthritis by suppressing both inflammatory and Th17 responses

Letter to the Editor

Failure of a metal on metal hip prostheses presenting as a destructive soft tissue mass due to ALVAL

Review

Vascular comorbidities in familial Mediterranean fever

Review

Coexistence of vasculitides with Familial Mediterranean Fever

Original Article

The investigation of toll-like receptor 3, 9 and 10 gene polymorphisms in Turkish rheumatoid arthritis patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits